about
Reporting bias in medical research - a narrative reviewConflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journalsWho has used internal company documents for biomedical and public health research and where did they find them?Medical ghost-writingMedicine. Moving toward transparency of clinical trials.Ethics, economics and the regulation and adoption of new medical devices: case studies in pelvic floor surgery.Dust diseases and the legacy of corporate manipulation of science and lawMast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam.Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studiesAdverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance.Medical guidelines and performance measures: the need to keep them free of industry influence.Challenges to physician-patient communication about medication use: a window into the skeptical patient's world.Principles for the ethical analysis of clinical and translational researchComparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles.How do authors of systematic reviews deal with research malpractice and misconduct in original studies? A cross-sectional analysis of systematic reviews and survey of their authorsFDA Policy and Cardiovascular Medicine.Doctors and medical science.mPGES-1 deletion impairs diuretic response to acute water loading.No short-cut in assessing trial quality: a case studyRofecoxib-Induced Deleterious Effects Escape Detection by Organismal Performance Assays.Overcoming obstacles in risk factor management in type 2 diabetes mellitus.Web-based intensive monitoring: from passive to active drug surveillance.Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil.Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.What can we learn from drug marketing efficiency?Fraud and deceit in medical research.Effective use of real-life events as tools for teaching-learning clinical pharmacology in a problem-based learning curriculum.Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet.Has the hunt for conflicts of interest gone too far? Yes.Direct to consumer advertising of drugs in Europe.Early termination of drug trials.Designing Safer Analgesics via μ-Opioid Receptor Pathways.On being a neurologist in industry.Clinical perspectives in drug safety and adverse drug reactions.Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.Gender differences in dispensed analgesics in Sweden during 2006-2015 - an observational, nationwide, whole-population study.Translational Aspects of Sphingolipid Metabolism in Renal Disorders.The Disposable Author: How Pharmaceutical Marketing Is Embraced within Medicine's Scholarly Literature.
P2860
Q21203744-3990F72A-03C2-4EB5-9B1E-B352DDD3D905Q24644642-5CD429B2-07B3-4D1C-B135-939226D33DB7Q28657906-E3230314-A196-4FDA-BF2A-6170DEC91FE6Q28744060-E116AF12-14AF-4BB3-8E56-F670D2976C23Q33322703-1037432C-E7E7-43DA-900A-6797EDB7729CQ33672431-C3D6FE51-BA3D-455D-8779-A36DE2140123Q33877894-9472AC1E-ECB9-4F22-AEF7-8020971D0451Q33999952-D55D8C30-4993-4C82-A9A7-5DE277833B6AQ34161193-84F899EC-AD0B-490C-B866-A300A1B9CD74Q34644792-4EE15EA2-E552-489A-8537-B5D15AAAEBD5Q35307754-7113F3FA-6465-4F80-9020-984925F5F8FAQ35684204-122BF121-6F36-4446-AFE2-00C1D2E7B3D7Q35734501-AA46C463-F0F7-42CD-AFEB-DD976F5B8064Q35744647-CAC7DC57-FE5B-41D7-A817-64828E85B1B8Q35943880-740F6C4E-4FFA-4E80-A338-2DAD59D9A748Q36100416-C75869F2-D46B-4EB2-B56F-D2C46EC782E3Q36233762-F825B095-458F-4FC7-A37D-1BF2FB15435DQ37190261-F22C00E7-3807-40FC-B457-5EA5CC6AC0F5Q37364134-433763FA-674B-4FED-991C-25957467424AQ37544505-1896B441-6C97-4C64-9D5E-A0F2291BD9BBQ37909519-81AE8967-9675-43F4-A5E0-A62B137CB742Q37946924-D42FF074-D560-4FAB-9A76-79718DD5F32CQ38051681-44AAD8B0-EFBD-4111-9C99-15713E60B8D9Q38078815-32F0DFDC-06B9-47A8-ACC0-3338689B7D05Q38674299-6D656D43-936A-4D9D-A4CD-1385BADF1D72Q38771635-E584E82A-4F55-40C3-827B-FBFA05A871F7Q39587380-1AE90F44-FFA8-4A47-AA15-B4FE62CFC5F3Q40158346-BFDDF3E8-77DF-41F4-B0A9-7D5AD6FF82F6Q41474958-1243D69A-7EDC-4B8D-90FE-FCFBA6DB8F60Q41833844-35121B4F-1028-4BFF-BDA7-445960509932Q42275125-28DA9285-E061-4140-9FDF-7E839C6342D6Q42375233-0C6D768A-F461-42E9-A4BA-FAB727A7E5C6Q42951671-6F5BE496-5D74-4332-877A-A3083A281838Q43075987-E2FCF171-7FD9-4237-B924-039B4AB54454Q46339463-468BA670-9FEC-4CF1-9E47-6D9CD304FD1FQ46975372-17511D64-8C87-4E57-B0EB-2877E248AC89Q47722462-9C23A081-5340-4039-88BD-DF2C33614B60Q49185146-1CFE3978-4561-4F4D-ADDA-E2180F781DF5Q49399657-1BA105FA-602D-4692-BD16-696935809CB9Q53042847-054CB4DF-CFB5-4A3C-800E-3A738B623568
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
What have we learnt from Vioxx?
@ast
What have we learnt from Vioxx?
@en
type
label
What have we learnt from Vioxx?
@ast
What have we learnt from Vioxx?
@en
prefLabel
What have we learnt from Vioxx?
@ast
What have we learnt from Vioxx?
@en
P2093
P1433
P1476
What have we learnt from Vioxx?
@en
P2093
Amos H Presler
David S Egilman
Joseph S Ross
P304
P356
10.1136/BMJ.39024.487720.68
P407
P577
2007-01-01T00:00:00Z